Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Subjects Clear all
Terminated Phase 2 Interventional

Evaluation of MST-188 in Acute Lower Limb Ischemia

NCT02093468
View directory record Official record
Conditions
Acute Limb Ischemia
Interventions
MST-188, Saline
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
4
States / cities
Little Rock, Arkansas • Tampa, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 30, 2026, 1:28 AM EDT
Suspended Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

NCT05491603
View directory record Official record
Conditions
Onychomycosis
Interventions
DBI-001, DBI-002, Aqueous Gel
Biological
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Encino, California • New Brighton, Minnesota • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

NCT02849873
View directory record Official record
Conditions
Acne
Interventions
IDP-123 Lotion, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

NCT02404350
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Upland, California • Aurora, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 30, 2026, 1:28 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
1,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
87
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Terminated Phase 2 Interventional

Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

NCT04936113
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FB-401
Biological
Lead sponsor
Forte Biosciences, Inc.
Industry
Eligibility
2 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
8
States / cities
Fremont, California • Lake City, Florida • Newnan, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.

NCT01173627
View directory record Official record
Conditions
Pain
Interventions
Test fentanyl citrate 400 mcg troche, Actiq 400 mcg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

NCT02277574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AMP-110, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Anniston, Alabama • Orlando, Florida • Palm Harbor, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash

NCT00891982
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CTGel/ BPO Wash, Soap Free Cleanser and CTGel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Coral Gables, Florida • Warren, Michigan • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail

NCT02798380
View directory record Official record
Conditions
Onychomycosis
Interventions
HTS-519 Insert
Drug
Lead sponsor
Hallux, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 30, 2026, 1:28 AM EDT
Recruiting Phase 2 Interventional

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

NCT06121180
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
ZIV-Aflibercept, Cemiplimab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 30, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Optimized Loading Response by JOURNEY II BCS Knee Increases Daily Physical Activity and Functions

NCT02335710
View directory record Official record
Conditions
Knee Injuries
Interventions
Journey II BCS TKA
Device
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 2 Interventional

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)

NCT01154374
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
MEBO Wound Ointment, Standard of Care (sterile saline moistened gauze)
Drug · Procedure
Lead sponsor
Skingenix, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 30, 2026, 1:28 AM EDT
Active, not recruiting Phase 1 Interventional

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

NCT04485013
View directory record Official record
Conditions
Cancer
Interventions
TTX-080, pembrolizumab, cetuximab, FOLFIRI
Drug
Lead sponsor
Tizona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets

NCT00853554
View directory record Official record
Conditions
Healthy
Interventions
Hydromorphone Hydrochloride tablet 8 mg, Dilaudid® tablet 8 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

NCT01309854
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone, Drug-drug Interaction, Amount of Pioglitazone in Blood
Interventions
fostamatinib, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

NCT02131662
View directory record Official record
Conditions
Leiomyoma
Interventions
BAY1002670, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 2 Interventional

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT01826461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PDI-192, Vehicle
Drug
Lead sponsor
PreCision Dermatology, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
San Diego, California • Chicago, Illinois • Normal, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects

NCT04531527
View directory record Official record
Conditions
Dermatitis, Phototoxic
Interventions
Butenafine HCl 1% (BAY1896425)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 30, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 30, 2026, 1:28 AM EDT
Recruiting Phase 1 Interventional

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

NCT05083754
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Retifanlimab, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 30, 2026, 1:28 AM EDT